European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC)…

Read MoreEuropean Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

Medicines and Healthcare Products Regulatory Agency authorizes G SK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults

Medicines and Healthcare Products Regulatory Agency authorizes G SK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults GSK plc (LSE/NYSE: GSK) today announced that the Medicines and…

Read MoreMedicines and Healthcare Products Regulatory Agency authorizes G SK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults